Literature DB >> 19787709

Cytochrome P450 enzymes and the heart.

Ketul R Chaudhary1, Sri Nagarjun Batchu, John M Seubert.   

Abstract

The cytochrome P450 monooxygenase system (CYP) is a multigene superfamily of heme-thiolate enzymes, which are important in the metabolism of foreign and endogenous compounds. Genetic variations, drug interactions, or pathophysiological factors can lead to reduced, absent, or increased enzymatic activity. This altered CYP activity greatly influences an individual's response to therapeutic treatment. What is not known is the impact of these changes on the many functional roles of CYP in physiological and pathophysiological processes of the heart. Many extrahepatic tissues, like heart, contain active P450 enzymes but lack information regarding their role in cellular injury or homeostasis. Much of our current knowledge about cardiac CYP has been limited to studies investigating the role of fatty acid metabolites in heart. Traditional risk factors including diabetes, smoking, and hypertension have well established links to cardiovascular disease. And new evidence strongly suggests exposure to chemicals and other environmental agents has a profound impact on the cardiovascular system. These risk factors can independently affect the expression and activity of CYP enzymes. Therefore, altered CYP activity is important from a detoxification as well as a bioactivation perspective. Considering CYP, interactions are greatly dependent on inherited differences or acquired changes in enzyme activity further research into their potential impact on pathogenesis, risk assessment, and therapy of heart disease is warranted. This review explores the expression of CYP isoforms, their functional roles, and the effects of genetic variation in the heart.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787709     DOI: 10.1002/iub.241

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  21 in total

1.  The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs.

Authors:  Ghezal Froogh; Sharath Kandhi; Roopa Duvvi; Yicong Le; Zan Weng; Norah Alruwaili; Jonathan O Ashe; Dong Sun; An Huang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-13       Impact factor: 4.733

2.  Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.

Authors:  Hsia-Lien Lin; Haoming Zhang; Vyvyca J Walker; Jaime D'Agostino; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2017-07-11       Impact factor: 3.922

3.  Female-favorable attenuation of coronary myogenic constriction via reciprocal activations of epoxyeicosatrienoic acids and nitric oxide.

Authors:  Ghezal Froogh; Jun Qin; Sharath Kandhi; Yicong Le; Houli Jiang; Meng Luo; Dong Sun; An Huang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-03-25       Impact factor: 4.733

4.  Myocardial pharmacokinetics of ebastine, a substrate for cytochrome P450 2J, in rat isolated heart.

Authors:  W Kang; S Elitzer; K Noh; T Bednarek; M Weiss
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

5.  Metabolism of arachidonic acid by the cytochrome P450 enzyme in patients with chronic Keshan disease and dilated cardiomyopathy.

Authors:  Bing Zhou; Shulan He; X I Wang; Xiaolong Zhen; Xiaohui Su; Wuhong Tan
Journal:  Biomed Rep       Date:  2015-12-31

6.  Anti-inflammatory ω-3 endocannabinoid epoxides.

Authors:  Daniel R McDougle; Josephine E Watson; Amr A Abdeen; Reheman Adili; Megan P Caputo; John E Krapf; Rodney W Johnson; Kristopher A Kilian; Michael Holinstat; Aditi Das
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-07       Impact factor: 11.205

7.  Anthracycline derivatives inhibit cardiac CYP2J2.

Authors:  Justin S Kim; Andres S Arango; Swapnil Shah; William R Arnold; Emad Tajkhorshid; Aditi Das
Journal:  J Inorg Biochem       Date:  2022-01-13       Impact factor: 4.155

8.  Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17α-Ethynylestradiol.

Authors:  Hsia-Lien Lin; Haoming Zhang; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2018-03-30       Impact factor: 3.922

9.  CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.

Authors:  Eric A Evangelista; Rozenn N Lemaitre; Nona Sotoodehnia; Sina A Gharib; Rheem A Totah
Journal:  Drug Metab Dispos       Date:  2018-01-17       Impact factor: 3.922

10.  Novel genetic associations with serum level metabolites identified by phenotype set enrichment analyses.

Authors:  Janina S Ried; So-Youn Shin; Jan Krumsiek; Thomas Illig; Fabian J Theis; Tim D Spector; Jerzy Adamski; H-Erich Wichmann; Konstantin Strauch; Nicole Soranzo; Karsten Suhre; Christian Gieger
Journal:  Hum Mol Genet       Date:  2014-06-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.